Protagonist Therapeutics, Inc.
(NASDAQ : PTGX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-3.80%191.441.2%$534.16m
TSROTESARO, Inc.
0.23%73.9514.4%$516.06m
CELGCelgene Corporation
-3.74%70.081.2%$510.98m
GILDGilead Sciences, Inc.
-2.91%68.150.9%$491.90m
ILMNIllumina, Inc.
-3.86%321.413.5%$363.96m
BIIBBiogen Inc.
-3.05%316.731.3%$352.14m
REGNRegeneron Pharmaceuticals, Inc.
-2.32%372.832.6%$248.08m
VRTXVertex Pharmaceuticals Incorporated
-4.12%172.211.9%$245.33m
AAgilent Technologies, Inc.
-2.34%70.231.5%$233.08m
ALXNAlexion Pharmaceuticals, Inc.
-4.49%115.602.0%$139.06m
SRPTSarepta Therapeutics, Inc.
-3.35%121.3815.4%$129.29m
NKTRNektar Therapeutics
-2.76%36.995.5%$106.49m
EXASExact Sciences Corporation
-4.30%71.7025.3%$105.84m
INCYIncyte Corporation
-0.91%64.512.5%$103.69m
LGNDLigand Pharmaceuticals Incorporated
-5.19%145.6123.1%$85.50m

Company Profile

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It offers proprietary peptide technology platform, which discovers and develops new chemical entities to address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.